BLISS GVS PHARMA LTD. - 506197 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shruti Vishal Rao & PACs BLISS GVS PHARMA LTD. - 506197 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shruti Vishal Rao & PACs BLISS GVS PHARMA LTD. - 506197 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copy of advertisement of public notice issued in respect of information regarding 37th Annual General Meeting of the Company scheduled to be held on Tuesday, June 28, 2022 at 11:00 a.m. (IST) through Video Conferencing ('VC")/Other Audio Visual Means ('OAVM'), in compliance with the General Circulars dated April 08, 2020, April 13, 2020, May 05, 2020 and January 13, 2021, December 08, 2021, December 14, 2021 and May 05, 2022 respectively issued by the Ministry of Corporate Affairs ('MCA Circulars') along with the Circular issued by Securities and Exchange Board of India ('SEBI Circular') dated May 12, 2020, January 15, 2021 and May 13, 2022 published in Free Press Journal and Navshakti - Mumbai newspapers on May 30, 2022. BLISS GVS PHARMA LTD. - 506197 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shruti Vishal Rao & PACs BLISS GVS PHARMA LTD. - 506197 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shruti Vishal Rao & PACs BLISS GVS PHARMA LTD. - 506197 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular no. CIR/CFD/CMD1/27/2019 dated 8th February, 2019, please find enclosed herewith Annual Secretarial Compliance Report of the Company for the financial year ended March 31, 2022. BLISS GVS PHARMA LTD. - 506197 - Disclosure Of Related Party Transactions Under Regulation 23(9) Of SEBI (LODR) Regulations, 2015
Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the disclosure of Related Party Transactions for the period from October 01, 2021 to March 31, 2022. BLISS GVS PHARMA LTD. - 506197 - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company BLISS GVS PHARMA LTD. 2 CIN NO. L24230MH1984PLC034771 3 Report filed for FY 2021-2022 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* FY 2021-2022, FY 2022-2023 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) 0 8Quantum of (d), which has been met from (c)(e)* 0 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* Nil Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)FY 2021-2022, FY2020-2021 Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-Aditi BhattDesignation :-Company Secretary Name of the Chief Financial Officer :- Vipul B Thakkar Designation : -Chief Financial Officer Date: 13/05/2022 BLISS GVS PHARMA LTD. - 506197 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
We would like to inform you that, the ESOP Allotment Committee of the Company at its meeting held on May 09, 2022 has approved the allotment of 84,250 equity shares of face value of Re. 1/- each to the eligible employees who have exercised their stock options under Bliss GVS Pharma Limited-Employee Stock Option Plan 2019 ('Bliss GVS ESOP-2019'). BLISS GVS PHARMA LTD. - 506197 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to the provision of Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the extract copies of newspaper advertisement of Audited Financial Results of the Company for the quarter and year ended March 31, 2022 published in 'The Economic Times - Mumbai & Ahmedabad' & The Free Press Journal' an English Daily and 'Maharashtra Times & Navshkati' a Regional Daily, on May 02, 2022.